Clinical Trial Results STEP trials (Semaglutide Treatment Effect in People with obesity): Average weight loss of ~15% of total body weight
How Medicard by iFinance Supports Canadians Medicard by iFinance does not prescribe medication or provide medical advice
Emerging Drug Classes Beyond GLP-1 Dominance While GLP-1 receptor agonists - especially oral options - have captured significant attention, the future of T2D therapies extends into multiple promising areas
We stock a comprehensive range of lyophilised research peptides including Retatrutide, BPC-157, BPC-157/TB-500 Blend, GHK-Cu, Melanotan 2, Ipamorelin, Tesamorelin, MOTS-C, and more all independently lab tested with Certificates of Analysis published for every batch on every product page
NICE guidance (NG28 for type 2 diabetes, TA875 for semaglutide 2.4 mg, and TA664 for liraglutide 3 mg) recommends regular monitoring of patients on GLP-1 therapy, with particular attention to tolerability and adverse effects
Glutathione can bind to heavy metals and other toxins to make them more water-soluble and thus easier to remove via stool and urine